ISS has renewed an existing contract with a global pharmaceutical company.

The new contract, which has a slightly changed scope will run for five years until April 2027.

Under the terms of the deal, ISS will deliver integrated facility management services to offices, plasma donation centres, and manufacturing sites in various regions globally via a team of approximately 1,000 employees.

The scope of services includes technical maintenance, facilities maintenance and repair, GMP cleaning and general cleaning, food and hospitality services, landscaping and security services as well as a broad variety of support services (mail, laundry, helpdesk, etc.).

The annual revenue of the contract is above 1% of Group revenue.

Commenting on the contract renewal, Andrew Price, interim CEO, Global Key Accounts, said: “I am very happy that we can continue our multi-year partnership on a global scale and keep supporting the important work that this company is doing in providing better health to the world. The contract is an acknowledgment of our many placemakers who have been delivering a dedicated service throughout the years.”